Split-dose or hybrid nonsteroidal anti-inflammatory drugs and N-acetylcysteine therapy for prevention of post-retrograde cholangiopancreatography pancreatitis

Table 1 Baseline characteristics of patients in the control group and the study groups

Characteristic	Control group (n = 98)	Study group A (n = 32)	Study group B (n = 56)	P
Female	44	14	40	0.059
Male	54	18	16	0.086
Age, yr	64.47	63.56	64.50	0.976
Comorbid conditions	68	24	40	0.910
Diabetes mellitus type 2	4	0	4	0.529
Hypertension	24	10	6	0.591
Ischemic heart disease	8	6	6	0.399
Dyslipidemia	8	7	7	0.247
Hypothyroidism	0	0	4	0.093
Hepatic cirrhosis	4	0	4	0.529
Normal bilirubin pre-ERCP	20	16	14	0.066
Previous cholecystectomy	40	10	24	0.734
Dilated bile duct pre-ERCP	4	0	4	0.529

ERCP: Endoscopic retrograde cholangiopancreatography.